section name header

Indications ⬇

High Alert

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: DEEP VEIN THROMBOSIS (DVT)

Derm: alopecia

EENT: epistaxis

GI: ↓appetite, stomatitis, vomiting, diarrhea, nausea

GU: ↓fertility, ↑serum creatinine

Hemat: anemia, leukopenia, neutropenia, thrombocytopenia

Neuro: peripheral neuropathy, weakness

Resp: INTERSTITIAL LUNG DISEASE (ILD), PULMONARY EMBOLISM (PE)

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Drug-Food:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Hepatic Impairment

US Brand Names ⬆ ⬇

Ibrance

Action ⬆ ⬇

  • Inhibits kinases (cyclin-dependent kinases 4 and 6) that are part of the signaling pathway for cell proliferation.
Therapeutic effects:
  • Improved survival and decreased spread of breast cancer.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: 46% absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized (by CYP3A and sulfontransferase); 6.9% excreted unchanged in urine, 2.3% in feces.

Half-Life: 29 hr.

Time/Action Profile ⬆ ⬇

( improvement in progression-free survival)

ROUTEONSETPEAKDURATION
POwithin 4 mounknownmaintained throughout treatment

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

pal-BO-sye-klib

Code ⬆

NDC Code